Posted on

cbd oil and morphine

From folk medicine and anecdotal reports it is known that Cannabis may reduce pain. In animal studies it has been shown that delta-9-tetrahydrocannabinol (THC) has antinociceptive effects or potentiates the antinociceptive effect of morphine. The aim of this study was to measure the analgesic effect of THC, morphine, and a THC-morphine combination (THC-morphine) in humans using experimental pain models. THC (20 mg), morphine (30 mg), THC-morphine (20 mg THC+30 mg morphine), or placebo were given orally and as single doses. Twelve healthy volunteers were included in the randomized, placebo-controlled, double-blinded, crossover study. The experimental pain tests (order randomized) were heat, cold, pressure, single and repeated transcutaneous electrical stimulation. Additionally, reaction time, side-effects (visual analog scales), and vital functions were monitored. For the pharmacokinetic profiling, blood samples were collected. THC did not significantly reduce pain. In the cold and heat tests it even produced hyperalgesia, which was completely neutralized by THC-morphine. A slight additive analgesic effect could be observed for THC-morphine in the electrical stimulation test. No analgesic effect resulted in the pressure and heat test, neither with THC nor THC-morphine. Psychotropic and somatic side-effects (sleepiness, euphoria, anxiety, confusion, nausea, dizziness, etc.) were common, but usually mild.

SAN FRANCISCO — “So let me know if you’ve ever seen a patient like this: 70-year-old guy, metastatic lung cancer, who’s using oxycodone. He’s using long-acting morphine for breathlessness and bone pain. He’s going to be starting chemo and immunotherapy soon. And, usually right as you’re walking out the door, he says, ‘Doc, should I be using that CBD [cannabidiol] that’s advertised everywhere?’

Zylla and his team have several studies in development, a few of which have already received funding. They are hoping to launch in early 2020.

Less Opiate Use?

He highlighted a survey published last year in the Journal of Clinical Oncology that showed that 80% of oncologists reported that they discussed cannabis use with their patients. Half had recommended it to their patients for “some reason or another, but only 30% felt comfortable talking about it,” he commented.

These were the questions posed by Daniel Bowles, MD, an associate professor of medicine-medical oncology at the University of Colorado, Boulder.

In his practice, he does bring this point up with patients who are receiving immunotherapies, telling them that “we just don’t know in this situation. If there are other agents that work as well to control your symptoms, maybe we should be trying those instead.”